140 related articles for article (PubMed ID: 9027600)
21. Lung cancer: chemoprevention and intermediate effect markers.
Tockman MS
IARC Sci Publ; 2001; 154():257-70. PubMed ID: 11220665
[TBL] [Abstract][Full Text] [Related]
22. Epidemiology of lung cancer.
Buiatti E; Geddes M; Arniani S
Ann Ist Super Sanita; 1996; 32(1):133-44. PubMed ID: 8967716
[TBL] [Abstract][Full Text] [Related]
23. [Biomarkers of gentotoxic risk and metabolic polymorphism].
Pavanello S; Clonfero E
Med Lav; 2000; 91(5):431-69. PubMed ID: 11189784
[TBL] [Abstract][Full Text] [Related]
24. GSTM1, GSTT1, and GSTP1 polymorphism and lung cancer risk in relation to tobacco smoking.
Schneider J; Bernges U; Philipp M; Woitowitz HJ
Cancer Lett; 2004 May; 208(1):65-74. PubMed ID: 15105047
[TBL] [Abstract][Full Text] [Related]
25. Smoking habit and genetic factors associated with lung cancer in a population highly exposed to arsenic.
Adonis M; Martínez V; Marín P; Berrios D; Gil L
Toxicol Lett; 2005 Oct; 159(1):32-7. PubMed ID: 16099114
[TBL] [Abstract][Full Text] [Related]
26. Application of biological markers to the study of lung cancer causation and prevention.
Perera FP; Santella RM; Brenner D; Young TL; Weinstein IB
IARC Sci Publ; 1988; (89):451-9. PubMed ID: 3198231
[TBL] [Abstract][Full Text] [Related]
27. [Molecular epidemiology and prevention of bronchopulmonary carcinoma].
De Flora S
Chir Ital; 1995; 47(3):1-12. PubMed ID: 8964091
[TBL] [Abstract][Full Text] [Related]
28. The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements.
Goodman GE; Thornquist MD; Balmes J; Cullen MR; Meyskens FL; Omenn GS; Valanis B; Williams JH
J Natl Cancer Inst; 2004 Dec; 96(23):1743-50. PubMed ID: 15572756
[TBL] [Abstract][Full Text] [Related]
29. Sensitivity to DNA damage induced by benzo(a)pyrene diol epoxide and risk of lung cancer: a case-control analysis.
Li D; Firozi PF; Wang LE; Bosken CH; Spitz MR; Hong WK; Wei Q
Cancer Res; 2001 Feb; 61(4):1445-50. PubMed ID: 11245449
[TBL] [Abstract][Full Text] [Related]
30. High benzo[a]pyrene diol-epoxide DNA adduct levels in lung and blood cells from individuals with combined CYP1A1 MspI/Msp-GSTM1*0/*0 genotypes.
Rojas M; Alexandrov K; Cascorbi I; Brockmöller J; Likhachev A; Pozharisski K; Bouvier G; Auburtin G; Mayer L; Kopp-Schneider A; Roots I; Bartsch H
Pharmacogenetics; 1998 Apr; 8(2):109-18. PubMed ID: 10022748
[TBL] [Abstract][Full Text] [Related]
31. Chemoprevention of lung cancer: soon daily practice?
van Zandwijk N; Pastorino U
Expert Rev Anticancer Ther; 2003 Feb; 3(1):91-8. PubMed ID: 12597353
[TBL] [Abstract][Full Text] [Related]
32. Interaction of cytochrome P4501A1 genotypes with other risk factors and susceptibility to lung cancer.
Shah PP; Singh AP; Singh M; Mathur N; Pant MC; Mishra BN; Parmar D
Mutat Res; 2008 Mar; 639(1-2):1-10. PubMed ID: 18082227
[TBL] [Abstract][Full Text] [Related]
33. Metabolic gene polymorphisms and lung cancer risk in non-smokers. An update of the GSEC study.
Raimondi S; Boffetta P; Anttila S; Bröckmoller J; Butkiewicz D; Cascorbi I; Clapper ML; Dragani TA; Garte S; Gsur A; Haidinger G; Hirvonen A; Ingelman-Sundberg M; Kalina I; Lan Q; Leoni VP; Le Marchand L; London SJ; Neri M; Povey AC; Rannug A; Reszka E; Ryberg D; Risch A; Romkes M; Ruano-Ravina A; Schoket B; Spinola M; Sugimura H; Wu X; Taioli E
Mutat Res; 2005 Dec; 592(1-2):45-57. PubMed ID: 16009381
[TBL] [Abstract][Full Text] [Related]
34. Chemoprevention of lung cancers: lessons from CARET, the beta-carotene and retinol efficacy trial, and prospects for the future.
Omenn GS
Eur J Cancer Prev; 2007 Jun; 16(3):184-91. PubMed ID: 17415088
[TBL] [Abstract][Full Text] [Related]
35. Impact of inherited polymorphisms in glutathione S-transferase M1, microsomal epoxide hydrolase, cytochrome P450 enzymes on DNA, and blood protein adducts of benzo(a)pyrene-diolepoxide.
Pastorelli R; Guanci M; Cerri A; Negri E; La Vecchia C; Fumagalli F; Mezzetti M; Cappelli R; Panigalli T; Fanelli R; Airoldi L
Cancer Epidemiol Biomarkers Prev; 1998 Aug; 7(8):703-9. PubMed ID: 9718223
[TBL] [Abstract][Full Text] [Related]
36. Molecular epidemiology of lung cancer in female passive smokers.
Yang M; Pyo MY
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2005; 23(1):75-97. PubMed ID: 16291523
[TBL] [Abstract][Full Text] [Related]
37. GSTM1, GSTT1 and GSTP1 polymorphisms, environmental tobacco smoke exposure and risk of lung cancer among never smokers: a population-based study.
Wenzlaff AS; Cote ML; Bock CH; Land SJ; Schwartz AG
Carcinogenesis; 2005 Feb; 26(2):395-401. PubMed ID: 15528218
[TBL] [Abstract][Full Text] [Related]
38. Smokers and urinary genotoxins: implications for selection of cohorts and modulation of endpoints in chemoprevention trials.
De Flora S; Camoirano A; Bagnasco M; Bennicelli C; van Zandwijk N; Wigbout G; Qian GS; Zhu YR; Kensler TW
J Cell Biochem Suppl; 1996; 25():92-8. PubMed ID: 9027604
[TBL] [Abstract][Full Text] [Related]
39. [Combined effects of genetic polymorphisms in cytochrome P450s and GSTM1 on lung cancer susceptibility].
Gu YF; Zhang ZD; Zhang SC; Zheng SH; Jia HY; Gu SX
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3064-8. PubMed ID: 18261353
[TBL] [Abstract][Full Text] [Related]
40. Molecular epidemiology: a new perspective for the study of toxic exposures in man. A consideration of the influence of genetic susceptibility factors on risk in different lung cancer histologies.
Caporaso NE; Landi MT
Med Lav; 1994; 85(1):68-77. PubMed ID: 8035747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
